A manuscript apparently containing the first description of an increased cancer risk in diabetic patients taking glargine insulin was submitted to Diabetologia which was eventually sent to six reviewers, three of whom recommended that the paper be rejected [Smith and Gale, 2009]. Here, INS is linked to cancer.